BSE filing, NSE: DRREDDY. Summary written from the filing by ALFA Finder's alert engine.
Dr. Reddy's Laboratories Ltd: key numbers
- Share price
- ₹1,369.90
- Market cap
- ₹1,14,342 Cr
- Revenue (annual)
- ₹33,700 Cr
- Net profit (annual)
- ₹4,196 Cr
- P/E (TTM)
- 40.8×Sector 41.3×
- Promoter holding
- 26.63%-0.01% QoQ
- FII holding
- 20.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Reddy's Laboratories Ltd
All →Dr. Reddy's Laboratories Price Movement Clarification
Dr. Reddy's confirms FDA tentative approval for its lenacapavir HIV shot. The company states the news is not material and has no material impact.
Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Dr. Reddy's Laboratories Earnings Call Transcript: Key Takeaways
Revenue declined 1.5% YoY as lower Revlimid sales in North America offset strong double-digit growth in base business and emerging markets.
- Call
- Guides 25% growth
Dr. Reddy's Laboratories Management Change
Dr Reddy's appointed Akhil Ravi as Head API and Services and Senior Management Personnel, effective 13 November 2026. Ravi is the son-in-law of co-chairman G V Prasad.
Dr. Reddy's Laboratories Investor Presentation: Key Takeaways
Q2FY27 revenue ₹8,671 Cr (-1.5% YoY), EBITDA ₹1,783 Cr (20.6%), PAT ₹925 Cr (-36% YoY). Management stresses double-digit base-business growth excluding lenalidomide in North America.
Dr. Reddy's Laboratories Q2 FY27 Results: Net Profit ₹913.2 Cr, Down 31.7% YoY
Dr. Reddy's Laboratories Ltd reported revenue from operations of ₹8,698 Cr (-1.5% YoY) and net profit of ₹913.2 Cr (-31.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹913.2 Cr · -31.7% YoY
Other employee stock options announcements
All →Sarla Performance Fibers Employee Stock Options
Sarla Performance Fibers issued a postal ballot notice seeking shareholder approval for a new ESOP Plan 2026 via an irrevocable trust, plus related special resolutions. E-voting runs 5 Nov to 4 Dec 2026.
- Execution
- E-voting 05 Nov 2026 to 04 Dec 2026
Keystone Realtors Employee Stock Options
Keystone Realtors approved allotment of 29,956 ESOP shares at ₹10 face value on November 4, 2026. The new shares rank pari-passu with existing equity.
JSW Steel Employee Stock Options
JSW Steel's ESOP welfare trust sold approximately 6.15 lakh shares across two plan accounts via NSE and off-market in late Oct/early Nov 2026, totalling about ₹0.62 Crore.
- Value
- ₹0.62 Cr
Capillary Technologies India Employee Stock Options
Capillary Technologies allotted 94,553 equity shares of ₹2 each upon exercise of vested ESOP 2021 options. The allotment was approved by circular resolution on November 04, 2026.
Inox India Employee Stock Options
INOX India allotted 43,852 equity shares of Rs.2 each under its ESOP 2022 scheme to eligible employees. The allotment increased paid-up capital with no fresh investment value.
CreditAccess Grameen Employee Stock Options
CreditAccess Grameen allotted 6,484 ESOP shares to 10 employees on 4 November 2026. Shares rank pari-passu with existing equity.